MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Role of uric acid as a prognostic biomarker in Idiopathic Parkinson’s disease and Parkinson Plus Syndrome

T. Modi, M. Goyal, J. Kaur, B. Medhi (Chandigarh, India)

Meeting: 2018 International Congress

Abstract Number: 1008

Keywords: Multiple system atrophy(MSA): Pathophysiology, Parkinsonism, Progressive supranuclear palsy(PSP)

Session Information

Date: Sunday, October 7, 2018

Session Title: Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus)

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: To estimate the levels of serum uric acid in Idiopathic Parkinson’s disease (IPD) and various Parkinson plus syndromes (PPS). To correlate the uric acid levels with duration and severity of illness and evaluate the role of serum uric acid as the diagnostic and prognostic marker in PD

Background: Uric acid is the end product of purine metabolism and is major antioxidant. The amount of uric acid in blood depends on dietary intake of purines, biosynthesis of uric acid and excretion. As a major antioxidant and having metal complexing properties, it is postulated to play an important role in preventing neurodegeneration in PD. Recent studies have shown an inverse association between high serum uric acid and risk of developing PD. We evaluated the role of serum uric acid as the diagnostic and prognostic marker in PD.

Methods: Current study included 99 patients with Parkinsonism and 68 healthy volunteers. Patients were diagnosed with IPD, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal ganglionic degeneration (CBGD) as per standard criteria. Written informed consent was obtained from all patients included in the study. All patients underwent UPDRS (Unified Parkinson Disease Rating Scale) and MRI brain. Serum Uric acid was estimated according to manufacturer’s instructions using Infinite Uric acid assay kit (Accurex Biomedical PVT.LTD., Mumbai, INDIA) on UV Spectrophotometer.

Results: Mean Serum Uric acid levels for total PD patients was 5.16 mg/dl and 7.45 mg/dl for controls. We found that there was a significant decrease of serum uric acid levels in cases compared to healthy controls (p<0.001). Our study also observed significant inverse correlation of serum Uric acid levels with age at onset (r = - 0.206, p= 0.04). However, our study did not find any correlation of serum Uric acid levels with disease severity as measured by UPDRS motor score III and H&Y staging. Besides this, no correlation of serum Uric acid levels with duration of illness was observed. There was no difference in serum uric acid levels between IPD and PPS (p=0.30).

Conclusions: Serum uric acid levels were significantly lower in PD as compared to controls. Uric acid levels showed inverse correlation with age at onset, but we could not find any significant difference in uric acid levels between PD and PPS groups, as well as the severity of disease.

References: 1. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med. 2010; 4(5): 701–12. 2. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D et al. Serum urate and probability of dopaminergic deficit in early Parkinson disease. Mov Disord 2011; 26(10): 1864–8. 3. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann. Neurol 1992;32(6): 804–12. 4. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000;149(1):43–50. 5. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, et al. Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord. 2016; 31(5):663-7.

To cite this abstract in AMA style:

T. Modi, M. Goyal, J. Kaur, B. Medhi. Role of uric acid as a prognostic biomarker in Idiopathic Parkinson’s disease and Parkinson Plus Syndrome [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/role-of-uric-acid-as-a-prognostic-biomarker-in-idiopathic-parkinsons-disease-and-parkinson-plus-syndrome/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/role-of-uric-acid-as-a-prognostic-biomarker-in-idiopathic-parkinsons-disease-and-parkinson-plus-syndrome/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley